Comments on: Vertex Announces European Commission Approval for KALYDECO® (ivacaftor) in Infants With Cystic Fibrosis Ages 6 Months to Less Than 12 Months With Certain Mutations in the CFTR Gene

Comments on: Vertex Announces European Commission Approval for KALYDECO® (ivacaftor) in Infants With Cystic Fibrosis Ages 6 Months to Less Than 12 Months With Certain Mutations in the CFTR Gene https://www.novumpr.nl/2019/12/10/vertex-announces-european-commission-approval-for-kalydeco-ivacaftor-in-infants-with-cystic-fibrosis-ages-6-months-to-less-than-12-months-with-certain-mutations-in-the-cftr-gene/?utm_source=rss&utm_medium=rss&utm_campaign=vertex-announces-european-commission-approval-for-kalydeco-ivacaftor-in-infants-with-cystic-fibrosis-ages-6-months-to-less-than-12-months-with-certain-mutations-in-the-cftr-gene NovumPR press releases Tue, 10 Dec 2019 12:56:00 +0000 hourly 1 https://wordpress.org/?v=6.8.3